This open-label Phase I trial (n=15) will investigate the effects of psilocybin (25mg) on brain function and cognitive control in healthy adults, using electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).
Conducted by Johns Hopkins University, this study aims to explore how psilocybin influences brain activity, particularly inhibitory responses measured through EEG during TMS. Participants will be adults aged 22–55 with prior experience using hallucinogens, but without recent use or psychiatric conditions. Researchers will measure changes in specific brain wave patterns and subjective experiences using the Mystical Experience Questionnaire (MEQ30). The study is expected to run from March 2025 to August 2026.
Trial Details
This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers. Participants will undergo experimental drug administration sessions after careful screening and preparation. Participants will also have brain activity measured using electroencephalogram (EEG) also during non-invasive brain stimulation using Transcranial Magnetic Stimulation (TMS).Trial Number NCT06835699
Sponsors & Collaborators
Johns Hopkins UniversityJohns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.